Exercise Measurement of Right Ventricular-arterial Coupling to Predict Hemodynamic Worsening in Heart Failure and Preserved Ejection Fraction
The investigators aim to evaluate the feasibility and prognostic value of right ventricular-arterial coupling (RVAC) during exercise in patients with HFpEF-PH using a hybrid technique of real-time CMRderived volume measures and CardioMEMS-derived pulmonary artery pressure measurements. The investigators will determine: 1. Whether exercise RV-arterial coupling at baseline (assessed using hybrid CMRCardioMEMS) predicts development or worsening of exercise RV-arterial uncoupling during follow-up in HFpEF-PH patients. 2. If HFpEF-PH patients developing RV dysfunction have a particular PAP pattern as assessed remotely using the CardioMEMS system. The investigators will determine differential characteristics in CardioMEMS pressure patterns in those developing RV dysfunction versus those who do not develop RV dysfunction, both at rest and during exercise. Hence, HFpEF-PH patients developing RV dysfunction may harbor a plateau of pulmonary artery pressures (as a reflection of RV-arterial uncoupling) despite clinical worsening. 3. Whether extraction of raw pressure data obtained by the CardioMEMS system is feasible and enables post-processing using machine learning methods (artificial intelligence) for deep phenotyping of patients (in addition to clinical evaluation of pressure waveforms). The investigators aim to evaluate the effect of SGLT-2 inhibitors on RV-arterial coupling in patients with HFpEF-PH. In case a patient is not using an SGLT-2 inhibitor, the investigators will prescribe this after baseline testing, since SGLT-2 inhibitors are clinically indicated in these patients.
• Written informed consent obtained from subject
• \> 18 years of age
• Diagnosis of NYHA Class III Heart Failure with preserved ejection fraction defined as LVEF≥45%
• At least 1 heart failure related hospitalization or urgent outpatient visit within 12 months of baseline visit
• Presence of pulmonary hypertension defined as mPAP\>25 mmHg at rest or mPAP/CO slope \>3 mmHg/L/min during exercise during right heart catheterization or tricuspid regurgitation velocity of \> 2.8 m/s assessed by transthoracic echocardiography (data must be taken within the last 6 months prior to implantation)
• Subjects with a BMI ≤ 35. Subjects with BMI \>35 will require their chest circumference to be measured at the axillary level, if \> 65 inches the patient will not be eligible for the study.
• Subjects with pulmonary artery branch diameter ≥ 7mm - (implant target artery - assessed during the RHC)
• Subjects willing and able to comply with the follow-up requirements of the study
• All participants need to be able to perform at least 40 watts on an upright bicycle stress test.